0000899243-22-034915.txt : 20221103 0000899243-22-034915.hdr.sgml : 20221103 20221103162802 ACCESSION NUMBER: 0000899243-22-034915 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221101 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renger John CENTRAL INDEX KEY: 0001830363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 221358468 MAIL ADDRESS: STREET 1: C/O CEREVEL THERAPEUTICS, INC. STREET 2: 51 ASHTOR PLACE CITY: NEW YORK STATE: NY ZIP: 10003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-01 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830363 Renger John C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 0 1 0 0 Chief Scientific Officer Common Stock 2022-11-01 4 M 0 10018 3.50 A 12722 D Common Stock 2022-11-01 4 M 0 14982 10.28 A 27704 D Common Stock 2022-11-01 4 S 0 25000 30.0002 D 2704 D Stock Option (Right to Buy) 3.50 2022-11-01 4 M 0 10018 0.00 D 2029-04-02 Common Stock 10018 60110 D Stock Option (Right to Buy) 10.28 2022-11-01 4 M 0 14982 0.00 D 2029-04-02 Common Stock 14982 104951 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 - $30.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. /s/ Mark Bodenrader, as Attorney-in-Fact 2022-11-03